A Mixed AdComm: REMS Seems Possible For GSK’s Anemia Drug, Dual Indication Likely Needs More Data
Executive Summary
Daprodustat gets a thumbs up from a US FDA advisory committee on one of two proposed indications, but panelists indicate preference for strong pharmacovigilance program for GSK’s oral anemia treatment for chronic kidney disease patients.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
FDA Says Safety Concerns May Negate Any Oral Dosing Advantage For GSK’s Anemia Treatment
When a drug’s biggest advantage becomes its potential downfall: The agency worries that chronic kidney disease patients not receiving dialysis may have worse outcomes on GSK’s anemia treatment daprodustat compared to ESA because of less patient safety monitoring as a result of the drug’s oral administration.